- There are nearly 100 local polypeptide enterprises in China, whose products are mainly generic drugs.
- In recent years, the reform and upgrading of the national pharmaceutical industry, the gradual implementation of various policies, the impact on the industry has gradually expanded.
- At present, nearly half of the peptide drugs on the market in the world have not yet been listed in China.
There are nearly 100 local polypeptide enterprises in China, whose products are mainly generic drugs.
Sinochem is a large-scale professional polypeptide pharmaceutical enterprise. The company has rich experience in research and development, registration and application, production and marketing of chemical synthetic peptide drugs, and has successfully developed a number of peptide drugs in the Chinese market.
The company’s polypeptide drugs mainly include thymosin for injection (“Jitai”), somatostatin for injection, thymopentin for injection, and bivalirudin for injection. It should be noted that the products of domestic polypeptide preparation enterprises are mostly imitations of foreign polypeptide drugs which have passed the patent protection period or have not applied for patents in China.
The competition is concentrated on thymopentin, thymopentin, somatostatin and other large polypeptide varieties. At the same time, the domestic peptide product line and dosage form are relatively single, mainly immune and emergency hemostatic drugs, and common lyophilized powder injection and common lyophilized powder injection are widely used Small volume injection dosage form, the industry competition is fierce.
In recent years, the reform and upgrading of the national pharmaceutical industry, the gradual implementation of various policies, the impact on the industry has gradually expanded.
The limitation of medical insurance reimbursement of the company’s main products leads to the limitation of the use of many patients and the difficulty of product market expansion. At the same time, seven new companies of the same type have been approved for listing in recent two years, which has intensified the market competition.
On the one hand, the fierce market competition combined with the state’s key monitoring of individual large varieties under the policy guidance of medical insurance cost control and fee reduction, the sales of traditional products represented by thymopentin and Thymosin showed a flat or obvious downward trend.
On the other hand, with the further standardized development of the pharmaceutical industry and the strengthening of environmental protection laws and regulations, the sales of traditional products have shown a flat or obvious downward trend The price of raw and auxiliary materials purchased by the company has increased to varying degrees, which also leads to the increase of production costs.
Although the peptide drug market in China started late, it has developed rapidly. The sales volume increased from 5.6 billion yuan in 2009 to 29.56 billion yuan in 2017, with an average annual compound growth rate of 23.12%. As a whole, China’s polypeptide drug market is still in the development stage.
Compared with foreign peptide pharmaceutical companies Novartis, Huiling pharmaceutical, prebiotics, syranox, AstraZeneca and Lilly, the R & D strength of Chinese peptide pharmaceutical enterprises is weak, and the product pipeline is relatively single. However, in the field of peptide generic drugs, many polypeptide pharmaceutical enterprises in China have shown competitiveness, and have successively realized the localization of bivalirudin, ganerik, sittrek, enfoviride, carbetoxine, atosiban acetate and etibatide.
At present, nearly half of the peptide drugs on the market in the world have not yet been listed in China.
It is certain that in the future, China’s polypeptide drug industry will still be dominated by generic drugs. 2014-2022 is the peak period of patent expiration of polypeptide drugs heavyweight varieties.
Among them, there are many global sales of more than US $1 billion such as gratirale, liraglutide, exenatide, goserelin, etc. (article / flying mouse of sina finance and economics listed company research institute)
For sale, buy peptides, purchase peptides, and buy peptides online, you can find the Chinese peptide company:
Shengnuo Biotechnology is a high-tech China polypeptide manufacturers,who has over 19 years experience for the biotechnology .Our Products involve peptide raw materials,polypeptide drug.
Our 0 defect has passed the FDA certification, and has become the first-class professional polypeptide drug and product development and large-scale production and export industry in China .
Our service scope：peptide synthesis、peptide hormones、peptide medicine、beauty peptide、peptide medicine product、peptide technology transfer、peptide technology service、peptide large-scale production、export of peptide
Thymopentin for Injection、 Thymalfasin for Injection 、 Bivalirudin 、Bulk Drug、 Liraglutide ……
How many companies are there in peptide api manufacturer in china? The peptide api market is very promising, and the world is encouraging the development of peptide business. There is a peptide api list on the website Biofda.com, which contains various specifications of peptide APIs for customers to choose from. Shengnuo Technology is a peptide api manufacturer located in Chengdu, a city in southwest China. Not only peptide APIs, but also carnosine custom suppliers and cosmetic peptide suppliers
are many peptide apis manufacture in China, but they are all small-scale companies. The China peptide company such as Sinotech is a leading company in China and has a very high position.
As a Chinese peptide company, Sinotech has been working silently, hoping to become a top peptide company in the world. There are many countries producing peptides in the world, such as bulk drug substance in India, gmp custom peptide in uk, and peptide production in usa. So what is polypeptide? What kind of peptide synthesis supplier should you choose? Follow our website: www.biofda.com, here will tell you the answer.